{"success":true,"data":{"pressRelease":{"id":"109936","rtpr_id":"nGNX7CNLTt","ticker":"TKNO","exchange":"NASDAQ","all_tickers":["TKNO"],"title":"Teknova Reports Second Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-08-05T20:01:01.961Z","article_body":"Second quarter 2026 total revenue was $12.2 million, up 18% over the same\nquarter prior year\nCompany raises 2026 revenue guidance to $45-47 million\nLaunched proprietary AI-powered Build-Tek™ custom order configurator,\ngiving developers a faster path from preclinical to clinical manufacturing\n\nHOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc.\n(“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of\ncritical reagents for the discovery, development, and commercialization of\nnovel therapies, vaccines, and molecular diagnostics, today announced\nfinancial results for the second quarter ended June 30, 2026.\n\n\"We delivered more than $12 million in quarterly revenue for the first time in\nTeknova's history, with growth across nearly all of the end markets we serve,\"\nsaid Stephen Gunstream, President and Chief Executive Officer at Teknova.\n\"These results demonstrate the impact of the investments we've made in our\ncommercial organization, state-of-the-art facilities, and manufacturing\nsystems, and strengthen our confidence in our ability to deliver long-term,\nsustainable growth as the biotech market continues to recover.\"\n\nMatt Lowell, Teknova’s Chief Financial Officer, added, “We delivered\nexcellent financial results in the second quarter 2026 compared to 2025,\nincluding 18% revenue growth and a significant improvement in Free Cash\nOutflow. We are therefore raising our 2026 revenue guidance to $45-47 million\nand adjusting down our expectations for full-year Free Cash Outflow to less\nthan $8 million,” he explained.\n\nCorporate and Financial Updates\n* Second quarter 2026 total revenue of $12.2 million, up 18% compared to $10.3\nmillion for the second quarter 2025\n* Total cash and short-term investments were $17.4 million and total\nborrowings were $13.2 million at the end of the second quarter 2026\n* Following a second quarter beta release, the Company launched Build-Tek™,\nthe AI-powered evolution of its proprietary custom configurator first\nintroduced in 2024, now enabling therapeutic and diagnostic developers to\nbuild complex custom products in just minutes\nRevenue for the Second Quarter 2026\n\n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n (Dollars in thousands) 2026 2025 2026 2025 \n Lab Essentials $ 9,184 $ 7,792 $ 17,579 $ 15,909 \n Clinical Solutions 2,428 2,060 4,573 3,222 \n Other 573 435 1,110 951 \n Total revenue $ 12,185 $ 10,287 $ 23,262 $ 20,082 \n \n \n\nSecond Quarter 2026 Financial Results\n\nTotal revenue for the second quarter 2026 was $12.2 million, up 18% compared\nto $10.3 million in the second quarter 2025. Lab Essentials revenue was $9.2\nmillion in the second quarter 2026, up 18% compared to $7.8 million in the\nsecond quarter 2025. Clinical Solutions revenue was $2.4 million in the second\nquarter 2026, up 18% compared to $2.1 million in the second quarter 2025.\n\nGross profit for the second quarter 2026 was $4.9 million, compared to $4.0\nmillion in the second quarter 2025. Gross margin for the second quarter 2026\nwas 40.1%, compared to 38.7% in the second quarter 2025. The increase in gross\nmargin was primarily driven by higher revenue, partially offset by higher\nfixed cost absorption into cost of goods sold from faster finished goods\ninventory turns. This compares to the same period in the prior year that had\nbenefited from unusually favorable manufacturing efficiency gains.\n\nOperating expenses for the second quarter 2026 were $7.8 million, compared to\n$7.4 million in the second quarter 2025. The increase was primarily driven by\nhigher spending in sales and marketing, a result of higher headcount and\nincreased marketing expenses, partially offset by lower general and\nadministrative expenses attributable to lower stock-based compensation\nexpense.\n\nNet loss for the second quarter 2026 was $3.2 million, or negative $0.06 per\ndiluted share, compared to $3.6 million, or negative $0.07 per diluted share,\nfor the second quarter 2025. Adjusted EBITDA for the second quarter 2026 was\nnegative $0.7 million, compared to negative $0.8 million for the second\nquarter 2025.\n\nCash used in operating activities for the second quarter 2026 was $0.5\nmillion, compared to $2.1 million of cash used in operating activities for the\nsecond quarter 2025. Free Cash Outflow was $0.6 million for the second quarter\n2026, compared to $2.3 million for the second quarter 2025.\n\nA full reconciliation of these non-GAAP measures to the most comparable GAAP\nmeasures is included at the end of this release.\n\nImproves 2026 Outlook\n\nTeknova raises its fiscal 2026 outlook for revenue and improves its outlook\nfor Free Cash Outflow. The Company now anticipates total revenue of $45\nmillion to $47 million for the fiscal year ending December 31, 2026\n(“2026”). The Company also now expects Free Cash Outflow of less than $8\nmillion for 2026.\n\nUpcoming Investor Conference Attendance\n\nSidoti Microcap Conference (Virtual)\nAugust 19-20, 2026\n\nROTH Healthcare Opportunities Conference (New York, NY)\nSeptember 29, 2026\n\nConference Call and Webcast\n\nTeknova will host a webcast and conference call on Wednesday, August 5, 2026,\nbeginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can\nlog onto the call from the Investor Relations\n(https://www.globenewswire.com/Tracker?data=6lzNFZIRMmPYOCT9_07xFoWNH7HodJqqJM_ua3zkZt4iecyic7oMmS4mrWSCQEL7y0EDZq_EL0Ci9lZ_aL7uZWEPnphEbcI_QvzWPyWs12rPZ779eB9TbkgqAX5h272hdG0LmcIbxEpdnwkO24qo4Q==)\nsection of the Teknova website or by using this link\n(https://www.globenewswire.com/Tracker?data=U3bi9YCNARSdkGHyZqo0ddx6_pBXffV76rYu7GjuRjvfpyfGn13q5RpFWC0S2qqshtx6x-Rv8H8ioRstP_gmoBMnCZwVHY6rhDKSWHq5h9g=).\nIf you would like to participate in the call, please register for the webcast\nhere\n(https://www.globenewswire.com/Tracker?data=dij-KRYrMr53bsGbCOlCPBReciafPBWjnKqGc2lmOzQ2aEA68Vi0WsPRkQPhn8q7SoIHOg9cYX4vOjpl8VY0QgUQuuaMfvUAkg8RWx43UrWs4goruBVu6K4_pAzas5H2ZQuN7d8V8f68F3ffPxnKTO7mBPYbYGVOcZavSkZrbX0=)\nto receive a unique PIN number and dial-in information. The webcast will be\navailable for replay on the Company’s website approximately two hours after\nthe event.\n\nAbout Teknova\n\nTeknova makes solutions possible. Since 1996, Teknova has been innovating the\nmanufacture of critical reagents for the life sciences industry to accelerate\nthe discovery and development of novel breakthroughs that will help people\nlive longer, healthier lives. We offer fully customizable solutions for every\nstage of the workflow, supporting industry leaders in genomics, molecular\ndiagnostics, and emerging therapeutic modalities. Our fast turnaround of\nhigh-quality agar plates, microbial culture and cryopreservation media,\nbuffers and reagents, and water helps our customers scale seamlessly from RUO\nto GMP. Headquartered in Hollister, California, with over 180,000 square feet\nof state-of-the-art facilities, Teknova’s modular manufacturing platform was\ndesigned by our team of scientists, engineers, and quality control experts to\nefficiently produce the foundational ingredients for the discovery and\ncommercialization of next-generation therapies.\n\nNon-GAAP Financial Measures\n\nThis press release contains financial measures that have not been calculated\nin accordance with U.S. generally accepted accounting principles (GAAP).\nTeknova uses the following non-GAAP financial measures in assessing the\nperformance of its business and the effectiveness of its business strategies:\n(a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).\n\nTeknova defines Adjusted EBITDA as net income (loss) adjusted for interest\nincome (expense), net, provision for (benefit from) income taxes, depreciation\nexpense, amortization of intangible assets, and stock-based compensation\nexpense. Adjusted EBITDA reflects further adjustments to eliminate the impact\nof certain items, including certain non-cash and other items that Teknova does\nnot consider representative of its ongoing operating performance.\n\nTeknova defines Free Cash Flow (Outflow) as cash provided by (used in)\noperating activities less purchases of property, plant, and equipment.\n\nTeknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press\nrelease because Teknova believes that analysts, investors, and other\ninterested parties frequently use these measures to evaluate companies in\nTeknova’s industry and that such measures facilitate comparisons on a\nconsistent basis across reporting periods. Teknova also believes such measures\nare helpful in highlighting trends in Teknova’s operating results because\nthey exclude items that are not indicative of Teknova’s core operating\nperformance. Investors should consider non-GAAP financial measures in addition\nto, and not as a substitute for, or as superior to, measures of financial\nperformance prepared in accordance with GAAP. The non-GAAP financial measures\npresented by Teknova may be different from the non-GAAP financial measures\nused by other companies.\n\nA full reconciliation of these non-GAAP measures to the most comparable GAAP\nmeasures is included at the end of this release.\n\nForward-Looking Statements\n\nStatements in this press release about future expectations, plans, and\nprospects, as well as any other statements regarding matters that are not\nhistorical facts, may constitute “forward-looking statements.” These\nstatements include, but are not limited to, statements relating to Teknova’s\nanticipated total revenue, including our expectations for 2026 revenue and\nFree Cash Outflow guidance, and other statements about Teknova’s business\nprospects, including about Teknova’s profitability, strategy of managing\noperating expenses, and long-term growth strategy. The words, without\nlimitation, “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “plan,”\n“potential,” “predict,” “project,” “should,” “target,”\n“will,” “would,” and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these or similar identifying words. These forward-looking statements\nare based on management’s current expectations and beliefs and are subject\nto risks and uncertainties, all of which are difficult to predict and many of\nwhich are beyond Teknova’s control and could cause actual results to differ\nmaterially and adversely from those described in the forward-looking\nstatements. These risks and uncertainties include, but are not limited to,\ndemand for Teknova’s products (including the potential delay to or pausing\nof customer orders); Teknova’s assessment of fundamental indicators of\nfuture demand across its target customer base; Teknova’s cash flows and\nrevenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and\nwarehousing; inventory management; risks related to global economic and\nmarketplace uncertainties, including those related to the conflicts in Ukraine\nand the Middle East; potential acquisitions and integration of other\ncompanies; and other factors discussed in the “Risk Factors” section of\nTeknova’s most recent periodic reports filed with the Securities and\nExchange Commission (“SEC”), including in Teknova’s Annual Report on\nForm 10-K for the year ended December 31, 2025, and subsequent Quarterly\nReports on Form 10-Q filed with the SEC, all of which you may obtain for free\non the SEC’s website at www.sec.gov. Although Teknova believes that the\nexpectations reflected in its forward-looking statements are reasonable,\nTeknova does not know whether its expectations will prove correct. You are\ncautioned not to place undue reliance on these forward-looking statements,\nwhich Teknova makes only as of the date hereof, even if they are repeated by\nTeknova subsequently. Teknova does not intend and shall have no obligation to\nupdate, amend, or clarify these forward-looking statements, except as may be\nrequired under applicable securities laws.\n\nInvestor Contact\nMatt Lowell\nChief Financial Officer\nmatt.lowell@teknova.com\n+1 831-637-1100\n\nMedia Contact\nJennifer Henry\nSenior Vice President, Marketing\njenn.henry@teknova.com\n+1 831-313-1259\n\n \n ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Revenue $ 12,185 $ 10,287 $ 23,262 $ 20,082 \n Cost of sales 7,300 6,303 14,593 13,091 \n Gross profit 4,885 3,984 8,669 6,991 \n Operating expenses: \n Research and development 554 581 1,163 1,133 \n Sales and marketing 2,122 1,573 4,250 3,213 \n General and administrative 4,812 4,929 9,870 10,421 \n Amortization of intangible assets 287 287 574 574 \n Total operating expenses 7,775 7,370 15,857 15,341 \n Loss from operations (2,890 ) (3,386 ) (7,188 ) (8,350 ) \n Other (expenses) income, net \n Interest expense, net (252 ) (165 ) (471 ) (309 ) \n Other adjustment to loan exit fee — — — 485 \n Other income 2 — 11 — \n Total other (expenses) income, net (250 ) (165 ) (460 ) 176 \n Loss before income taxes (3,140 ) (3,551 ) (7,648 ) (8,174 ) \n Provision for income taxes 30 19 77 41 \n Net loss $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Net loss per share—basic and diluted $ (0.06 ) $ (0.07 ) $ (0.14 ) $ (0.15 ) \n Weighted average shares used in computing net loss per share—basic and diluted 53,634,826 53,448,736 53,614,671 53,435,210 \n \n\n\n\n ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) \n \n As of June 30, As of December 31, \n 2026 2025 \n ASSETS \n Current assets: \n Cash and cash equivalents $ 6,004 $ 5,912 \n Short-term investments, held-to-maturity 11,432 15,426 \n Accounts receivable, net 5,408 4,618 \n Inventories, net 6,911 7,054 \n Prepaid expenses and other current assets 1,069 1,501 \n Total current assets 30,824 34,511 \n Property, plant, and equipment, net 39,311 41,733 \n Operating right-of-use lease assets 13,247 14,112 \n Intangible assets, net 11,369 11,943 \n Other non-current assets 1,127 1,285 \n Total assets $ 95,878 $ 103,584 \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities: \n Accounts payable $ 1,438 $ 1,378 \n Accrued liabilities 3,476 4,283 \n Current portion of operating lease liabilities 1,958 1,876 \n Total current liabilities 6,872 7,537 \n Deferred tax liabilities 956 879 \n Long-term debt, net 13,218 13,123 \n Long-term operating lease liabilities 12,232 13,270 \n Total liabilities 33,278 34,809 \n Stockholders’ equity: \n Preferred stock — — \n Common stock 1 1 \n Additional paid-in capital 206,114 204,564 \n Accumulated deficit (143,515 ) (135,790 ) \n Total stockholders’ equity 62,600 68,775 \n Total liabilities and stockholders’ equity $ 95,878 $ 103,584 \n \n\n\n\n ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Operating activities: \n Net loss $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Adjustments to reconcile net loss to net cash used in operating activities: \n Bad debt expense (2 ) 4 5 49 \n Inventory reserve 412 488 825 925 \n Depreciation and amortization 1,593 1,590 3,169 3,170 \n Stock-based compensation 622 950 1,317 1,802 \n Deferred taxes 31 20 77 41 \n Accrued interest income on short-term investments 34 108 7 54 \n Amortization of discount on short-term investments (58 ) (171 ) (145 ) (355 ) \n Amortization of debt financing costs 48 43 95 129 \n Other adjustment to loan exit fee — — — (485 ) \n Non-cash lease expense 14 31 29 61 \n Loss on disposal of property, plant, and equipment 24 19 24 19 \n Changes in operating assets and liabilities: \n Accounts receivable 266 472 (795 ) (877 ) \n Inventories (449 ) (1,525 ) (682 ) (1,734 ) \n Prepaid expenses and other current assets 155 (36 ) 312 (40 ) \n Other non-current assets 68 (29 ) 158 34 \n Accounts payable (172 ) (360 ) 158 380 \n Accrued liabilities 113 (135 ) (659 ) (1,152 ) \n Other — — — (10 ) \n Cash used in operating activities (471 ) (2,101 ) (3,830 ) (6,204 ) \n Investing activities: \n Purchases of short-term investments (3,930 ) (7,765 ) (7,868 ) (9,735 ) \n Maturities of short-term investments 6,000 10,000 12,000 16,000 \n Purchases of property, plant, and equipment (125 ) (207 ) (346 ) (413 ) \n Cash provided by investing activities 1,945 2,028 3,786 5,852 \n Financing activities: \n Proceeds from long-term debt — — — 1,110 \n Payment of exit fee costs — — — (1,110 ) \n Repayment of financed insurance premiums — — (97 ) (56 ) \n Proceeds from exercise of stock options 170 16 179 20 \n Proceeds from issuance of common stock under employee stock purchase plan 54 56 54 56 \n Payment of debt issuance costs — (100 ) — (100 ) \n Cash provided by (used in) financing activities 224 (28 ) 136 (80 ) \n Change in cash and cash equivalents 1,698 (101 ) 92 (432 ) \n Cash and cash equivalents at beginning of period 4,306 3,377 5,912 3,708 \n Cash and cash equivalents at end of period $ 6,004 $ 3,276 $ 6,004 $ 3,276 \n \n\n\n\n ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Net loss – as reported $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Add back: \n Interest expense, net (252 ) (165 ) (471 ) (309 ) \n Provision for income taxes 30 19 77 41 \n Depreciation expense 1,306 1,303 2,595 2,596 \n Amortization of intangible assets 287 287 574 574 \n EBITDA $ (1,295 ) $ (1,796 ) $ (4,008 ) $ (4,695 ) \n Other and non-recurring expenses: \n Stock-based compensation expense 622 950 1,317 1,802 \n Other adjustment to loan exit fee — — — (485 ) \n Adjusted EBITDA $ (673 ) $ (846 ) $ (2,691 ) $ (3,378 ) \n \n\n\n\n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Cash used in operating activities $ (471 ) $ (2,101 ) $ (3,830 ) $ (6,204 ) \n Purchases of property, plant, and equipment (125 ) (207 ) (346 ) (413 ) \n Free Cash Flow $ (596 ) $ (2,308 ) $ (4,176 ) $ (6,617 ) \n \n \n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b4992253-8b06-4ba7-93c8-e1f9938c6556)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7CNLTt","title":"Teknova Reports Second Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"TKNO","created":"2026-08-05T20:01:01.961Z","tickers":["TKNO"],"exchange":"NASDAQ","article_body":"Second quarter 2026 total revenue was $12.2 million, up 18% over the same\nquarter prior year\nCompany raises 2026 revenue guidance to $45-47 million\nLaunched proprietary AI-powered Build-Tek™ custom order configurator,\ngiving developers a faster path from preclinical to clinical manufacturing\n\nHOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc.\n(“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of\ncritical reagents for the discovery, development, and commercialization of\nnovel therapies, vaccines, and molecular diagnostics, today announced\nfinancial results for the second quarter ended June 30, 2026.\n\n\"We delivered more than $12 million in quarterly revenue for the first time in\nTeknova's history, with growth across nearly all of the end markets we serve,\"\nsaid Stephen Gunstream, President and Chief Executive Officer at Teknova.\n\"These results demonstrate the impact of the investments we've made in our\ncommercial organization, state-of-the-art facilities, and manufacturing\nsystems, and strengthen our confidence in our ability to deliver long-term,\nsustainable growth as the biotech market continues to recover.\"\n\nMatt Lowell, Teknova’s Chief Financial Officer, added, “We delivered\nexcellent financial results in the second quarter 2026 compared to 2025,\nincluding 18% revenue growth and a significant improvement in Free Cash\nOutflow. We are therefore raising our 2026 revenue guidance to $45-47 million\nand adjusting down our expectations for full-year Free Cash Outflow to less\nthan $8 million,” he explained.\n\nCorporate and Financial Updates\n* Second quarter 2026 total revenue of $12.2 million, up 18% compared to $10.3\nmillion for the second quarter 2025\n* Total cash and short-term investments were $17.4 million and total\nborrowings were $13.2 million at the end of the second quarter 2026\n* Following a second quarter beta release, the Company launched Build-Tek™,\nthe AI-powered evolution of its proprietary custom configurator first\nintroduced in 2024, now enabling therapeutic and diagnostic developers to\nbuild complex custom products in just minutes\nRevenue for the Second Quarter 2026\n\n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n (Dollars in thousands) 2026 2025 2026 2025 \n Lab Essentials $ 9,184 $ 7,792 $ 17,579 $ 15,909 \n Clinical Solutions 2,428 2,060 4,573 3,222 \n Other 573 435 1,110 951 \n Total revenue $ 12,185 $ 10,287 $ 23,262 $ 20,082 \n \n \n\nSecond Quarter 2026 Financial Results\n\nTotal revenue for the second quarter 2026 was $12.2 million, up 18% compared\nto $10.3 million in the second quarter 2025. Lab Essentials revenue was $9.2\nmillion in the second quarter 2026, up 18% compared to $7.8 million in the\nsecond quarter 2025. Clinical Solutions revenue was $2.4 million in the second\nquarter 2026, up 18% compared to $2.1 million in the second quarter 2025.\n\nGross profit for the second quarter 2026 was $4.9 million, compared to $4.0\nmillion in the second quarter 2025. Gross margin for the second quarter 2026\nwas 40.1%, compared to 38.7% in the second quarter 2025. The increase in gross\nmargin was primarily driven by higher revenue, partially offset by higher\nfixed cost absorption into cost of goods sold from faster finished goods\ninventory turns. This compares to the same period in the prior year that had\nbenefited from unusually favorable manufacturing efficiency gains.\n\nOperating expenses for the second quarter 2026 were $7.8 million, compared to\n$7.4 million in the second quarter 2025. The increase was primarily driven by\nhigher spending in sales and marketing, a result of higher headcount and\nincreased marketing expenses, partially offset by lower general and\nadministrative expenses attributable to lower stock-based compensation\nexpense.\n\nNet loss for the second quarter 2026 was $3.2 million, or negative $0.06 per\ndiluted share, compared to $3.6 million, or negative $0.07 per diluted share,\nfor the second quarter 2025. Adjusted EBITDA for the second quarter 2026 was\nnegative $0.7 million, compared to negative $0.8 million for the second\nquarter 2025.\n\nCash used in operating activities for the second quarter 2026 was $0.5\nmillion, compared to $2.1 million of cash used in operating activities for the\nsecond quarter 2025. Free Cash Outflow was $0.6 million for the second quarter\n2026, compared to $2.3 million for the second quarter 2025.\n\nA full reconciliation of these non-GAAP measures to the most comparable GAAP\nmeasures is included at the end of this release.\n\nImproves 2026 Outlook\n\nTeknova raises its fiscal 2026 outlook for revenue and improves its outlook\nfor Free Cash Outflow. The Company now anticipates total revenue of $45\nmillion to $47 million for the fiscal year ending December 31, 2026\n(“2026”). The Company also now expects Free Cash Outflow of less than $8\nmillion for 2026.\n\nUpcoming Investor Conference Attendance\n\nSidoti Microcap Conference (Virtual)\nAugust 19-20, 2026\n\nROTH Healthcare Opportunities Conference (New York, NY)\nSeptember 29, 2026\n\nConference Call and Webcast\n\nTeknova will host a webcast and conference call on Wednesday, August 5, 2026,\nbeginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can\nlog onto the call from the Investor Relations\n(https://www.globenewswire.com/Tracker?data=6lzNFZIRMmPYOCT9_07xFoWNH7HodJqqJM_ua3zkZt4iecyic7oMmS4mrWSCQEL7y0EDZq_EL0Ci9lZ_aL7uZWEPnphEbcI_QvzWPyWs12rPZ779eB9TbkgqAX5h272hdG0LmcIbxEpdnwkO24qo4Q==)\nsection of the Teknova website or by using this link\n(https://www.globenewswire.com/Tracker?data=U3bi9YCNARSdkGHyZqo0ddx6_pBXffV76rYu7GjuRjvfpyfGn13q5RpFWC0S2qqshtx6x-Rv8H8ioRstP_gmoBMnCZwVHY6rhDKSWHq5h9g=).\nIf you would like to participate in the call, please register for the webcast\nhere\n(https://www.globenewswire.com/Tracker?data=dij-KRYrMr53bsGbCOlCPBReciafPBWjnKqGc2lmOzQ2aEA68Vi0WsPRkQPhn8q7SoIHOg9cYX4vOjpl8VY0QgUQuuaMfvUAkg8RWx43UrWs4goruBVu6K4_pAzas5H2ZQuN7d8V8f68F3ffPxnKTO7mBPYbYGVOcZavSkZrbX0=)\nto receive a unique PIN number and dial-in information. The webcast will be\navailable for replay on the Company’s website approximately two hours after\nthe event.\n\nAbout Teknova\n\nTeknova makes solutions possible. Since 1996, Teknova has been innovating the\nmanufacture of critical reagents for the life sciences industry to accelerate\nthe discovery and development of novel breakthroughs that will help people\nlive longer, healthier lives. We offer fully customizable solutions for every\nstage of the workflow, supporting industry leaders in genomics, molecular\ndiagnostics, and emerging therapeutic modalities. Our fast turnaround of\nhigh-quality agar plates, microbial culture and cryopreservation media,\nbuffers and reagents, and water helps our customers scale seamlessly from RUO\nto GMP. Headquartered in Hollister, California, with over 180,000 square feet\nof state-of-the-art facilities, Teknova’s modular manufacturing platform was\ndesigned by our team of scientists, engineers, and quality control experts to\nefficiently produce the foundational ingredients for the discovery and\ncommercialization of next-generation therapies.\n\nNon-GAAP Financial Measures\n\nThis press release contains financial measures that have not been calculated\nin accordance with U.S. generally accepted accounting principles (GAAP).\nTeknova uses the following non-GAAP financial measures in assessing the\nperformance of its business and the effectiveness of its business strategies:\n(a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).\n\nTeknova defines Adjusted EBITDA as net income (loss) adjusted for interest\nincome (expense), net, provision for (benefit from) income taxes, depreciation\nexpense, amortization of intangible assets, and stock-based compensation\nexpense. Adjusted EBITDA reflects further adjustments to eliminate the impact\nof certain items, including certain non-cash and other items that Teknova does\nnot consider representative of its ongoing operating performance.\n\nTeknova defines Free Cash Flow (Outflow) as cash provided by (used in)\noperating activities less purchases of property, plant, and equipment.\n\nTeknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press\nrelease because Teknova believes that analysts, investors, and other\ninterested parties frequently use these measures to evaluate companies in\nTeknova’s industry and that such measures facilitate comparisons on a\nconsistent basis across reporting periods. Teknova also believes such measures\nare helpful in highlighting trends in Teknova’s operating results because\nthey exclude items that are not indicative of Teknova’s core operating\nperformance. Investors should consider non-GAAP financial measures in addition\nto, and not as a substitute for, or as superior to, measures of financial\nperformance prepared in accordance with GAAP. The non-GAAP financial measures\npresented by Teknova may be different from the non-GAAP financial measures\nused by other companies.\n\nA full reconciliation of these non-GAAP measures to the most comparable GAAP\nmeasures is included at the end of this release.\n\nForward-Looking Statements\n\nStatements in this press release about future expectations, plans, and\nprospects, as well as any other statements regarding matters that are not\nhistorical facts, may constitute “forward-looking statements.” These\nstatements include, but are not limited to, statements relating to Teknova’s\nanticipated total revenue, including our expectations for 2026 revenue and\nFree Cash Outflow guidance, and other statements about Teknova’s business\nprospects, including about Teknova’s profitability, strategy of managing\noperating expenses, and long-term growth strategy. The words, without\nlimitation, “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “plan,”\n“potential,” “predict,” “project,” “should,” “target,”\n“will,” “would,” and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these or similar identifying words. These forward-looking statements\nare based on management’s current expectations and beliefs and are subject\nto risks and uncertainties, all of which are difficult to predict and many of\nwhich are beyond Teknova’s control and could cause actual results to differ\nmaterially and adversely from those described in the forward-looking\nstatements. These risks and uncertainties include, but are not limited to,\ndemand for Teknova’s products (including the potential delay to or pausing\nof customer orders); Teknova’s assessment of fundamental indicators of\nfuture demand across its target customer base; Teknova’s cash flows and\nrevenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and\nwarehousing; inventory management; risks related to global economic and\nmarketplace uncertainties, including those related to the conflicts in Ukraine\nand the Middle East; potential acquisitions and integration of other\ncompanies; and other factors discussed in the “Risk Factors” section of\nTeknova’s most recent periodic reports filed with the Securities and\nExchange Commission (“SEC”), including in Teknova’s Annual Report on\nForm 10-K for the year ended December 31, 2025, and subsequent Quarterly\nReports on Form 10-Q filed with the SEC, all of which you may obtain for free\non the SEC’s website at www.sec.gov. Although Teknova believes that the\nexpectations reflected in its forward-looking statements are reasonable,\nTeknova does not know whether its expectations will prove correct. You are\ncautioned not to place undue reliance on these forward-looking statements,\nwhich Teknova makes only as of the date hereof, even if they are repeated by\nTeknova subsequently. Teknova does not intend and shall have no obligation to\nupdate, amend, or clarify these forward-looking statements, except as may be\nrequired under applicable securities laws.\n\nInvestor Contact\nMatt Lowell\nChief Financial Officer\nmatt.lowell@teknova.com\n+1 831-637-1100\n\nMedia Contact\nJennifer Henry\nSenior Vice President, Marketing\njenn.henry@teknova.com\n+1 831-313-1259\n\n \n ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Revenue $ 12,185 $ 10,287 $ 23,262 $ 20,082 \n Cost of sales 7,300 6,303 14,593 13,091 \n Gross profit 4,885 3,984 8,669 6,991 \n Operating expenses: \n Research and development 554 581 1,163 1,133 \n Sales and marketing 2,122 1,573 4,250 3,213 \n General and administrative 4,812 4,929 9,870 10,421 \n Amortization of intangible assets 287 287 574 574 \n Total operating expenses 7,775 7,370 15,857 15,341 \n Loss from operations (2,890 ) (3,386 ) (7,188 ) (8,350 ) \n Other (expenses) income, net \n Interest expense, net (252 ) (165 ) (471 ) (309 ) \n Other adjustment to loan exit fee — — — 485 \n Other income 2 — 11 — \n Total other (expenses) income, net (250 ) (165 ) (460 ) 176 \n Loss before income taxes (3,140 ) (3,551 ) (7,648 ) (8,174 ) \n Provision for income taxes 30 19 77 41 \n Net loss $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Net loss per share—basic and diluted $ (0.06 ) $ (0.07 ) $ (0.14 ) $ (0.15 ) \n Weighted average shares used in computing net loss per share—basic and diluted 53,634,826 53,448,736 53,614,671 53,435,210 \n \n\n\n\n ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) \n \n As of June 30, As of December 31, \n 2026 2025 \n ASSETS \n Current assets: \n Cash and cash equivalents $ 6,004 $ 5,912 \n Short-term investments, held-to-maturity 11,432 15,426 \n Accounts receivable, net 5,408 4,618 \n Inventories, net 6,911 7,054 \n Prepaid expenses and other current assets 1,069 1,501 \n Total current assets 30,824 34,511 \n Property, plant, and equipment, net 39,311 41,733 \n Operating right-of-use lease assets 13,247 14,112 \n Intangible assets, net 11,369 11,943 \n Other non-current assets 1,127 1,285 \n Total assets $ 95,878 $ 103,584 \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities: \n Accounts payable $ 1,438 $ 1,378 \n Accrued liabilities 3,476 4,283 \n Current portion of operating lease liabilities 1,958 1,876 \n Total current liabilities 6,872 7,537 \n Deferred tax liabilities 956 879 \n Long-term debt, net 13,218 13,123 \n Long-term operating lease liabilities 12,232 13,270 \n Total liabilities 33,278 34,809 \n Stockholders’ equity: \n Preferred stock — — \n Common stock 1 1 \n Additional paid-in capital 206,114 204,564 \n Accumulated deficit (143,515 ) (135,790 ) \n Total stockholders’ equity 62,600 68,775 \n Total liabilities and stockholders’ equity $ 95,878 $ 103,584 \n \n\n\n\n ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Operating activities: \n Net loss $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Adjustments to reconcile net loss to net cash used in operating activities: \n Bad debt expense (2 ) 4 5 49 \n Inventory reserve 412 488 825 925 \n Depreciation and amortization 1,593 1,590 3,169 3,170 \n Stock-based compensation 622 950 1,317 1,802 \n Deferred taxes 31 20 77 41 \n Accrued interest income on short-term investments 34 108 7 54 \n Amortization of discount on short-term investments (58 ) (171 ) (145 ) (355 ) \n Amortization of debt financing costs 48 43 95 129 \n Other adjustment to loan exit fee — — — (485 ) \n Non-cash lease expense 14 31 29 61 \n Loss on disposal of property, plant, and equipment 24 19 24 19 \n Changes in operating assets and liabilities: \n Accounts receivable 266 472 (795 ) (877 ) \n Inventories (449 ) (1,525 ) (682 ) (1,734 ) \n Prepaid expenses and other current assets 155 (36 ) 312 (40 ) \n Other non-current assets 68 (29 ) 158 34 \n Accounts payable (172 ) (360 ) 158 380 \n Accrued liabilities 113 (135 ) (659 ) (1,152 ) \n Other — — — (10 ) \n Cash used in operating activities (471 ) (2,101 ) (3,830 ) (6,204 ) \n Investing activities: \n Purchases of short-term investments (3,930 ) (7,765 ) (7,868 ) (9,735 ) \n Maturities of short-term investments 6,000 10,000 12,000 16,000 \n Purchases of property, plant, and equipment (125 ) (207 ) (346 ) (413 ) \n Cash provided by investing activities 1,945 2,028 3,786 5,852 \n Financing activities: \n Proceeds from long-term debt — — — 1,110 \n Payment of exit fee costs — — — (1,110 ) \n Repayment of financed insurance premiums — — (97 ) (56 ) \n Proceeds from exercise of stock options 170 16 179 20 \n Proceeds from issuance of common stock under employee stock purchase plan 54 56 54 56 \n Payment of debt issuance costs — (100 ) — (100 ) \n Cash provided by (used in) financing activities 224 (28 ) 136 (80 ) \n Change in cash and cash equivalents 1,698 (101 ) 92 (432 ) \n Cash and cash equivalents at beginning of period 4,306 3,377 5,912 3,708 \n Cash and cash equivalents at end of period $ 6,004 $ 3,276 $ 6,004 $ 3,276 \n \n\n\n\n ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) \n \n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Net loss – as reported $ (3,170 ) $ (3,570 ) $ (7,725 ) $ (8,215 ) \n Add back: \n Interest expense, net (252 ) (165 ) (471 ) (309 ) \n Provision for income taxes 30 19 77 41 \n Depreciation expense 1,306 1,303 2,595 2,596 \n Amortization of intangible assets 287 287 574 574 \n EBITDA $ (1,295 ) $ (1,796 ) $ (4,008 ) $ (4,695 ) \n Other and non-recurring expenses: \n Stock-based compensation expense 622 950 1,317 1,802 \n Other adjustment to loan exit fee — — — (485 ) \n Adjusted EBITDA $ (673 ) $ (846 ) $ (2,691 ) $ (3,378 ) \n \n\n\n\n For the Three Months For the Six Months \n Ended June 30, Ended June 30, \n 2026 2025 2026 2025 \n Cash used in operating activities $ (471 ) $ (2,101 ) $ (3,830 ) $ (6,204 ) \n Purchases of property, plant, and equipment (125 ) (207 ) (346 ) (413 ) \n Free Cash Flow $ (596 ) $ (2,308 ) $ (4,176 ) $ (6,617 ) \n \n \n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b4992253-8b06-4ba7-93c8-e1f9938c6556)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-05T20:01:02.504535603Z","server_sent_at_ms":1785960062504},"received_at":"2026-08-05T20:01:02.556Z","source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339649/0/en/teknova-reports-second-quarter-2026-financial-results.html"},"analysis":{"id":"98941","press_release_id":"109936","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Teknova reported Q2 2026 revenue of $12.2 million, up 18% year-over-year, driven by growth across Lab Essentials and Clinical Solutions.\n\nThe company raised its full-year 2026 revenue guidance to $45-47 million and improved its outlook for Free Cash Outflow to less than $8 million.\n\nAdditionally, Teknova launched Build-Tek, a proprietary AI-powered configurator designed to accelerate the transition from preclinical to clinical manufacturing.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Record revenue quarter with 18% growth and raised guidance highlights recovery in biotech end markets."},"keyFigures":{"revenue":12185000,"guidance":"2026 revenue $45-47 million; Free Cash Outflow less than $8 million","revenueYoy":"18%","customDimensions":{"gross_profit":4885000}},"quotedText":"We delivered more than $12 million in quarterly revenue for the first time in Teknova's history, with growth across nearly all of the end markets we serve","namedEntities":{"people":[{"name":"Stephen Gunstream","role":"President and CEO"},{"name":"Matt Lowell","role":"CFO"}],"products":["Build-Tek™"],"companies":[{"name":"Alpha Teknova, Inc.","ticker":"TKNO"}],"dollarAmounts":[{"amount":"$12.2 million","context":"Q2 2026 revenue"},{"amount":"$45-47 million","context":"2026 revenue guidance"},{"amount":"$17.4 million","context":"total cash and short-term investments"}]},"materialImpact":{"score":4,"reasoning":"Revenue grew 18% year-over-year to $12.2 million, marking a quarterly record, and the company raised full-year revenue guidance. Free cash outflow also improved significantly from $2.3 million to $0.6 million."},"tickerRelevance":{"others":[],"primary":"TKNO"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["guidance_update","product_launch"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"beat-and-raise"}},"event_type":"earnings","event_type_secondary":["guidance_update","product_launch"],"sentiment":"bullish","material_impact_score":4,"narrative":"Teknova reported Q2 2026 revenue of $12.2 million, up 18% year-over-year, driven by growth across Lab Essentials and Clinical Solutions.\n\nThe company raised its full-year 2026 revenue guidance to $45-47 million and improved its outlook for Free Cash Outflow to less than $8 million.\n\nAdditionally, Teknova launched Build-Tek, a proprietary AI-powered configurator designed to accelerate the transition from preclinical to clinical manufacturing.","key_figures":{"revenue":12185000,"guidance":"2026 revenue $45-47 million; Free Cash Outflow less than $8 million","revenueYoy":"18%","customDimensions":{"gross_profit":4885000}},"named_entities":{"people":[{"name":"Stephen Gunstream","role":"President and CEO"},{"name":"Matt Lowell","role":"CFO"}],"products":["Build-Tek™"],"companies":[{"name":"Alpha Teknova, Inc.","ticker":"TKNO"}],"dollarAmounts":[{"amount":"$12.2 million","context":"Q2 2026 revenue"},{"amount":"$45-47 million","context":"2026 revenue guidance"},{"amount":"$17.4 million","context":"total cash and short-term investments"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T22:54:38.741Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"beat-and-raise"}},"durationMs":178523,"modelName":"glm-4.7"}}